

REMARKS

Claims 65-75 are currently pending. Claims 65 and 71 are amended. Support for the amendments may be found in the specification, for example, at paragraphs 6-13, 25-29, 14-19, 20-24, 30, 31, 50-61 and Figure 1C. Claims 76-80 are cancelled without prejudice to the prosecution of any cancelled subject matter in other applications.

Claims 65-80 are rejected under 35 U.S.C. §112, ¶ 1, for lack of written description. For reasons set forth below, the rejection should be withdrawn and the pending claims should be allowed to issue.

The Examiner has rejected claim 65 because “the specification supports only [a] method of producing mammalian dendritic Langerhans type cells.” In response, Applicants have amended claim 65. In view of the amendments to claim 65, Applicants respectfully request withdrawal of this rejection.

The Examiner has also rejected claims 65, 71 and 76 because Example 6 discloses “producing human Langerhans cells by a specific method comprising more specific steps than are recited in the claims.” In response, Applicants have amended claims 65 and 71, and canceled claim 76 without prejudice. In view of the amendments to claims 65 and 71 and the cancellation of claim 76, Applicants respectfully request withdrawal of this rejection.

The Examiner has further rejected claims 65 and 71 because Example 6 provides an analysis employing specific antibodies. In response, Applicants have amended claims 65 and 71. In view of the amendments to claims 65 and 71, Applicants respectfully request withdrawal of this rejection.


The Examiner has finally rejected claim 76 because paragraphs 7-13 and 20-24 of the specification do not disclose the use of mouse peripheral blood monocytes. In response,

Applicants have canceled claim 76 without prejudice. In view of the cancellation of claim 76,
Applicants respectfully request withdrawal of this rejection.

CONCLUSION

Entry of the foregoing amendments and remarks into the file of the above-
identified application is respectfully requested. Withdrawal of all rejections is requested.

Respectfully submitted,



Ling Zhong
Patent Office Reg. No. 48,290

Lisa B. Kole
Patent Office Reg. No. 35,225
(212) 408-2628
Attorneys for Applicants
BAKER BOTTS L.L.P.
30 Rockefeller Plaza
New York, NY 10112--4498